<DOC>
	<DOCNO>NCT00470834</DOCNO>
	<brief_summary>Dutasteride inhibit conversion testosterone dihydrotestosterone ( DHT ) male hormone lead benign prostate growth . By block conversion testosterone DHT , dutasteride could allow bicalutamide effective anti-androgen thus prolong bicalutamide 's efficacy .</brief_summary>
	<brief_title>Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion criterion : Men ≥40 ≤90 year age Must asymptomatic prostate cancer progress androgen deprivation therapy ( rise PSA ) . PSA progression must occur firstline treatment GnRH analogue ( e.g . leuprolide , goserelin ) orchiectomy . PSA progression define three rise PSA measure least 4 week apart within previous year . Serum PSA ≥2 ≤20ng/ml central laboratory . One PSA retest central laboratory allow value &lt; 2 &gt; 20ng/ml ; PSA value consistent previous rise PSA value determine progression GnRH analogue . Serum Testosterone &lt; 50ng/ml central laboratory . Nonmetastatic prostate cancer confirm prior bone scan perform within 8 week screen . Expected survival ≥ 2 year ECOG Performance status 0 , 1 , 2 Exclusion criterion : Additional hormonal therapy ( exclude current use GnRH analogue ) within past 6 month : Estrogens ( e.g . megestrol , medroxyprogesterone , cyproterone , DES ) Drugs antiandrogenic property ( e.g. , spironolactone &gt; 50mg/day , flutamide , bicalutamide* , ketoconazole** , progestational agent ) *The use antiandrogen GnRH analogue induction &lt; 6 week acceptable , none within 3 month prior study entry . **The use topical ketoconazole permit prior study . NOTE : Use dietary herbal supplement ( e.g. , selenium , Vitamin E , saw palmetto ) , exclude daily vitamin , study discourage , prohibit . All dietary herbal supplement usage record eCRF . Treatment oral glucocorticoid 3 month prior randomization expectation use study . Prior chemotherapy prostate cancer . ( prior prostatectomy radiotherapy prostate allow ) Prostate surgery include TUNA , TURP , TUIP , laser treatment , thermotherapy , balloon dilatation , prosthesis , cryosurgical ablation within 2 month prior enrollment . Current and/or previous use follow medication : Finasteride ( Proscar , Propecia ) , Dutasteride ( GI198745 , AVODART ) exposure within 6 month prior study entry Anabolic steroid ( within 6 month prior study entry ) Participation investigational market drug trial within 30 day prior first dose study drug anytime study period . Any unstable serious coexist medical condition ( ) include limited myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes ; peptic ulcer disease uncontrolled medical management . Abnormal liver function test great 1.5 time upper limit normal alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , alkaline phosphatase [ ALP ] bilirubin . Serum creatinine &gt; 2.0 time upper limit normal . History another malignancy within five year could affect treatment prostate cancer survival subject . History current evidence drug alcohol abuse within last 12 month . History illness ( include psychiatric ) , opinion investigator , might confound result study pose additional risk subject . Known hypersensitivity 5 alphareductase inhibitor drug chemically related dutasteride .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>androgen deprivation therapy</keyword>
</DOC>